DataVXACS Applied Materials & InterfacesPaper
journal article·2021-03-03

Aptamer-Peptide Conjugates as Targeted Chemosensitizers for Breast Cancer Treatment

Yan Tan, Yingying Li, Yi-Xin Qu, Yuanye Su, Yongbo Peng, Zilong Zhao, Ting Fu, Xue-Qiang Wang, Weihong Tan

ACS Applied Materials & Interfaces· Volume 13· Issue 8
Publisher page
Source abstract

Abstract

High levels of heat shock protein 70 (HSP70) in tumors are commonly associated with poor prognosis, enhanced doxorubicin (DOX)-induced cardiotoxicity, and even drug resistance in DOX-related cancer chemotherapy. Several peptides possess remarkable protein inhibition and chemosensitization effects, which are attributed to their specific targeting ability against HSP70. However, the inherent poor cell penetration capacity considerably restricts the biomedical applications of these peptides. We herein describe the design and development of anti-MUC1 aptamer-peptide conjugates (ApPCs) as targeted chemosensitizers to overcome the above-mentioned issues. Moreover, DOX could be loaded on the ApPC to deliver the DOX-enclosed agent ApPC-DOX, which simultaneously acts as a targeted chemosensitizer and anticancer agent for combating drug resistance in breast cancer therapy. This innovative, engineered biocompatible conjugate not only enhances the sensitivity of DOX-resistant cells but also alleviates cardiotoxicity of DOX in vivo, highlighting the success of this targeted chemosensitizer strategy.
Source: openalex_inverted_index · Quality: baseline

Research context

Biomaterials

OpenAlex topics: Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery · Peptidase Inhibition and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Molecular Sciences and Biomedicine Laboratory (MBL), State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, and Aptamer Engineering Center of Hunan Province, Hunan University, Changsha 410082, P. R. China

Institute of Molecular Medicine (IMM), Renji Hospital, Shanghai Jiao Tong University School of Medicine, and College of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai 200240, P. R. China

The Cancer Hospital of the University of Chinese Academy of Sciences, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China

Funding

Ministry of Science and Technology of the People's Republic of China · China Scholarship Council · National Natural Science Foundation of China · Hunan Province

References (47)

Show source-provided references
1. 10.1016/j.jconrel.2016.03.04010.1016/j.jconrel.2016.03.040 ↗
2. 10.1016/j.bbcan.2013.12.00210.1016/j.bbcan.2013.12.002 ↗
3. 10.1016/j.jconrel.2011.02.01510.1016/j.jconrel.2011.02.015 ↗
4. 10.1002/med.2128010.1002/med.21280 ↗
5. 10.1038/s41598-019-38986-w10.1038/s41598-019-38986-w ↗
6. 10.1038/cddis.2013.49610.1038/cddis.2013.496 ↗
7. 10.1161/JAHA.119.01233810.1161/JAHA.119.012338 ↗
8. 10.1016/j.canlet.2015.02.02610.1016/j.canlet.2015.02.026 ↗
9. 10.2174/187152061866618081711495210.2174/1871520618666180817114952 ↗
10. 10.2174/138945011866617082312124810.2174/1389450118666170823121248 ↗
11. 10.1186/s12953-014-0057-y10.1186/s12953-014-0057-y ↗
12. 10.1002/advs.20160032710.1002/advs.201600327 ↗
13. 10.1002/1873-3468.1291310.1002/1873-3468.12913 ↗
14. 10.1038/s41419-017-0160-y10.1038/s41419-017-0160-y ↗
15. 10.18632/oncotarget.1732110.18632/oncotarget.17321 ↗
16. 10.1074/jbc.M51204420010.1074/jbc.M512044200 ↗
17. Yokota S.-i. · Cancer Res. · 2000 · 60 · 2942
18. 10.2147/IJN.S10982210.2147/IJN.S109822 ↗
19. 10.1038/nrurol.2014.32010.1038/nrurol.2014.320 ↗
20. 10.1158/0008-5472.CAN-10-144310.1158/0008-5472.CAN-10-1443 ↗
21. 10.1016/j.canlet.2017.01.01510.1016/j.canlet.2017.01.015 ↗
22. 10.1021/acs.molpharmaceut.7b0056010.1021/acs.molpharmaceut.7b00560 ↗
23. 10.3390/cancers1002004710.3390/cancers10020047 ↗
24. 10.1007/s00239-015-9716-610.1007/s00239-015-9716-6 ↗
25. 10.1039/C5SC02631H10.1039/C5SC02631H ↗
26. 10.1002/wnan.143810.1002/wnan.1438 ↗
27. 10.1021/acs.bioconjchem.0c0025010.1021/acs.bioconjchem.0c00250 ↗
28. 10.1021/jacs.9b1240910.1021/jacs.9b12409 ↗
29. 10.1021/jacs.9b1051010.1021/jacs.9b10510 ↗
30. 10.1021/acs.jcim.9b0075610.1021/acs.jcim.9b00756 ↗
31. 10.1002/med.2146210.1002/med.21462 ↗
32. 10.1016/j.molmed.2014.02.00710.1016/j.molmed.2014.02.007 ↗
33. 10.1159/00009608510.1159/000096085 ↗
34. 10.1021/acs.molpharmaceut.7b0090010.1021/acs.molpharmaceut.7b00900 ↗
35. 10.1016/j.jiec.2017.07.02510.1016/j.jiec.2017.07.025 ↗
36. 10.1002/wnan.154310.1002/wnan.1543 ↗
37. 10.1002/anie.20060225110.1002/anie.200602251 ↗
38. 10.1371/journal.pone.003343410.1371/journal.pone.0033434 ↗
39. 10.1016/j.jconrel.2006.05.01610.1016/j.jconrel.2006.05.016 ↗
40. 10.18632/oncotarget.943110.18632/oncotarget.9431 ↗
41. 10.1002/anie.20180136110.1002/anie.201801361 ↗
42. 10.1096/fj.11-19153610.1096/fj.11-191536 ↗
43. 10.1016/S1074-5521(98)90156-910.1016/S1074-5521(98)90156-9 ↗
44. 10.1007/s10495-015-1122-410.1007/s10495-015-1122-4 ↗
45. 10.1021/jacs.7b0506410.1021/jacs.7b05064 ↗
46. 10.1038/am.2015.1910.1038/am.2015.19 ↗
47. 10.1021/ja508802410.1021/ja5088024 ↗